LDS/Medical Tests/c-KIT Mutation Analysis, Tissue

c-KIT Mutation Analysis, Tissue

c-KIT is a proto-oncogene that encodes a Type-III transmembrane tyrosine kinase receptor. c-KIT and its ligand stem cell factor play a key role in survival, proliferation, differentiation, and functional activation of hematopoietic progenitor cells. c-Kit is expressed at high levels in hematopoietic stem cells, mast cells, melanocytic cells, germ cells, and the interstitial cells of Cajal. c-KIT mutations are reported in nearly all systemic mastocytosis cases with the most common being Asp816Val c-KIT mutation, 20% – 40% of core-binding factor (CBF) acute myeloid leukemia (AML) cases (those with t(8;21)(q22;q22) and inv(16)(p13q22) genomic rearrangements), and approximately 20% of assayed high-grade myelodysplastic syndrome (MDS) and MDS-derived AML patients.

A c-KIT mutation in AML confers increased risk of relapse and decreased overall survival. c-KIT mutation is also seen in 80 - 85% of gastrointestinal stromal tumors (GIST, GI Stromal Tumor). c-Kit (CD117) antigen is usually detected by IHC (immunohistochemistry). Identification of this mutation can lead to improved patient care. For example, a tyrosine kinase inhibitor, such as imatinib, has been evaluated to treat GI stromal tumors, systemic mastocytosis and c-KIT-positive AML and MDS. The Asp816Val mutation in systemic mastocytosis is relevant to patient therapy because it confers resistance to the drug imatinib. The treatment was found effective as a single reagent or combination therapy in those without this mutation.

  • As an aid in diagnosis of mastocytosis
  • As an aid in evaluation of acute myeloid leukemia
  • As an aid in evaluation of myelodysplastic syndrome
  • As an aid in diagnosis of gastrointestinal stromal tumors (GIST)
  • As an aid in diagnosis of melanoma
  • Disease management and therapy monitoring

Increased in (positive for mutation):

  • Systemic mastocytosis
  • Acute myeloid leukemia
  • Myelodysplastic syndrome
  • Myelodysplastic syndrome derived AML
  • Gastrointestinal stromal tumors
  • Myeloproliferative disorders
  • Melanoma
  • Lymphoma
  • Seminoma

 

Negative (Mutation not detected)
 

 

  • Polymerase Chain Reaction (PCR) and ASPE
  • High Performance Liquid Chromatography (HPLC)
  • DNA Sequence Analysis

Paraffin-embedded tissue, formalin-fixed tissue, frozen tissue, Whole blood, bone marrow.

CBC with Manual Differential, FLT3 Mutation, Leukemia Profile by Flow Cytometry, Cytogenetics (Chromosomal Analysis), other Acute Myeloid Leukemia Translocations and Immunophenotype Markers.
Approximately 1 week.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login